APO Research
Talk to an analyst

APO RESEARCH · REPORT

Renin-Angiotensin-System (RAS)-Acting Agent

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Renin-Angiotensin-System (RAS)-Acting Agent Market Analysis and Forecast 2026-2032

22 December 2025198 pages

Choose your research edition.

Industry ResearchRenin-Angiotensin-System (RAS)-Acting Agent Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Renin-Angiotensin-System (RAS)-Acting Agent Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Renin-Angiotensin-System (RAS)-Acting Agent market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Renin-Angiotensin-System (RAS)-Acting Agent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Renin-Angiotensin-System (RAS)-Acting Agent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Renin-Angiotensin-System (RAS)-Acting Agent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Renin-Angiotensin-System (RAS)-Acting Agent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent include Takeda Pharmaceutical Company Limited, Sanofi S.A., Johnson & Johnson, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company,Limited, AstraZeneca plc and Bristol-Myers Squibb Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Renin-Angiotensin-System (RAS)-Acting Agent, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Renin-Angiotensin-System (RAS)-Acting Agent, also provides the sales of main regions and countries. Of the upcoming market potential for Renin-Angiotensin-System (RAS)-Acting Agent, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Renin-Angiotensin-System (RAS)-Acting Agent sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Renin-Angiotensin-System (RAS)-Acting Agent market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Renin-Angiotensin-System (RAS)-Acting Agent sales, projected growth trends, production technology, application and end-user industry.

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Company

Takeda Pharmaceutical Company Limited

Sanofi S.A.

Johnson & Johnson

Novartis AG

Merck & Co., Inc.

Pfizer, Inc.

Daiichi Sankyo Company,Limited

AstraZeneca plc

Bristol-Myers Squibb Company

Boehringer lngelheim GmbH

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Type

Angiotensin Converting Enzyme Inhibitors (ACEi)

Angiotensin Receptor Blockers (ARBs)

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Application

Heart Failure

Chronic Kidney Disease

Hypertension

Other

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Renin-Angiotensin-System (RAS)-Acting Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Renin-Angiotensin-System (RAS)-Acting Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Renin-Angiotensin-System (RAS)-Acting Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Renin-Angiotensin-System (RAS)-Acting Agent in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Renin-Angiotensin-System (RAS)-Acting Agent manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Renin-Angiotensin-System (RAS)-Acting Agent sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Angiotensin Converting Enzyme Inhibitors (ACEi) Major Manufacturers Table 3. Angiotensin Receptor Blockers (ARBs) Major Manufacturers Table 4. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Heart Failure Major Manufacturers Table 6. Chronic Kidney Disease Major Manufacturers Table 7. Hypertension Major Manufacturers Table 8. Other Major Manufacturers Table 9. Renin-Angiotensin-System (RAS)-Acting Agent Industry Trends Table 10. Renin-Angiotensin-System (RAS)-Acting Agent Industry Drivers Table 11. Renin-Angiotensin-System (RAS)-Acting Agent Industry Opportunities and Challenges Table 12. Renin-Angiotensin-System (RAS)-Acting Agent Industry Restraints Table 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2021-2026) Table 17. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2027-2032) Table 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 19. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2026) & (k units) Table 20. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2027-2032) & (k units) Table 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2021-2026) Table 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2027-2032) Table 23. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Manufacturers (2021-2026) Table 27. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Price (US$/unit) of Manufacturers (2021-2026) Table 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Renin-Angiotensin-System (RAS)-Acting Agent Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers, Product Type & Application Table 31. Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Renin-Angiotensin-System (RAS)-Acting Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2026) Table 38. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2027-2032) Table 39. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type 2021 VS 2025 VS 2032 (k units) Table 40. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (k units) Table 41. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2027-2032) & (k units) Table 42. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2026) Table 43. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2027-2032) Table 44. Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2021-2026) & (US$/unit) Table 45. Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2027-2032) & (US$/unit) Table 46. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2021-2026) Table 50. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2027-2032) Table 51. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application 2021 VS 2025 VS 2032 (k units) Table 52. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026) & (k units) Table 53. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2027-2032) & (k units) Table 54. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2026) Table 55. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2027-2032) Table 56. Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2021-2026) & (US$/unit) Table 57. Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2027-2032) & (US$/unit) Table 58. Takeda Pharmaceutical Company Limited Company Information Table 59. Takeda Pharmaceutical Company Limited Business Overview Table 60. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 62. Takeda Pharmaceutical Company Limited Recent Development Table 63. Sanofi S.A. Company Information Table 64. Sanofi S.A. Business Overview Table 65. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 67. Sanofi S.A. Recent Development Table 68. Johnson & Johnson Company Information Table 69. Johnson & Johnson Business Overview Table 70. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 72. Johnson & Johnson Recent Development Table 73. Novartis AG Company Information Table 74. Novartis AG Business Overview Table 75. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 77. Novartis AG Recent Development Table 78. Merck & Co., Inc. Company Information Table 79. Merck & Co., Inc. Business Overview Table 80. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 82. Merck & Co., Inc. Recent Development Table 83. Pfizer, Inc. Company Information Table 84. Pfizer, Inc. Business Overview Table 85. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 87. Pfizer, Inc. Recent Development Table 88. Daiichi Sankyo Company,Limited Company Information Table 89. Daiichi Sankyo Company,Limited Business Overview Table 90. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 92. Daiichi Sankyo Company,Limited Recent Development Table 93. AstraZeneca plc Company Information Table 94. AstraZeneca plc Business Overview Table 95. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 97. AstraZeneca plc Recent Development Table 98. Bristol-Myers Squibb Company Company Information Table 99. Bristol-Myers Squibb Company Business Overview Table 100. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 102. Bristol-Myers Squibb Company Recent Development Table 103. Boehringer lngelheim GmbH Company Information Table 104. Boehringer lngelheim GmbH Business Overview Table 105. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 107. Boehringer lngelheim GmbH Recent Development Table 108. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2026) & (US$ Million) Table 109. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2027-2032) & (US$ Million) Table 110. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (k units) Table 111. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2027-2032) & (k units) Table 112. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2021-2026) & (US$/unit) Table 113. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2027-2032) & (US$/unit) Table 114. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2026) & (US$ Million) Table 115. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2027-2032) & (US$ Million) Table 116. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026) & (k units) Table 117. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2027-2032) & (k units) Table 118. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2021-2026) & (US$/unit) Table 119. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2027-2032) & (US$/unit) Table 120. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 122. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 123. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 124. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 125. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 126. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Country (2021-2026) & (US$/unit) Table 127. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Country (2027-2032) & (US$/unit) Table 128. United States Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 129. Canada Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 130. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 131. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2026) & (US$ Million) Table 132. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2027-2032) & (US$ Million) Table 133. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (k units) Table 134. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2027-2032) & (k units) Table 135. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2021-2026) & (US$/unit) Table 136. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2027-2032) & (US$/unit) Table 137. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2026) & (US$ Million) Table 138. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2027-2032) & (US$ Million) Table 139. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026) & (k units) Table 140. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2027-2032) & (k units) Table 141. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2021-2026) & (US$/unit) Table 142. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2027-2032) & (US$/unit) Table 143. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 145. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 146. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 147. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 148. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 149. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Country (2021-2026) & (US$/unit) Table 150. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Country (2027-2032) & (US$/unit) Table 151. Germany Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 152. France Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 153. U.K. Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 154. Italy Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 155. Russia Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 156. Spain Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 157. Netherlands Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 158. Switzerland Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 159. Sweden Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 160. Poland Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 161. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2026) & (US$ Million) Table 162. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2027-2032) & (US$ Million) Table 163. China Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (k units) Table 164. China Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2027-2032) & (k units) Table 165. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2021-2026) & (US$/unit) Table 166. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2027-2032) & (US$/unit) Table 167. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2026) & (US$ Million) Table 168. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2027-2032) & (US$ Million) Table 169. China Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026) & (k units) Table 170. China Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2027-2032) & (k units) Table 171. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2021-2026) & (US$/unit) Table 172. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2027-2032) & (US$/unit) Table 173. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2026) & (US$ Million) Table 174. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2027-2032) & (US$ Million) Table 175. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (k units) Table 176. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2027-2032) & (k units) Table 177. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2021-2026) & (US$/unit) Table 178. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2027-2032) & (US$/unit) Table 179. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2026) & (US$ Million) Table 180. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2027-2032) & (US$ Million) Table 181. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026) & (k units) Table 182. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2027-2032) & (k units) Table 183. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2021-2026) & (US$/unit) Table 184. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2027-2032) & (US$/unit) Table 185. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 186. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 187. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 188. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 189. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 190. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 191. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Country (2021-2026) & (US$/unit) Table 192. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Country (2027-2032) & (US$/unit) Table 193. Japan Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 194. South Korea Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 195. India Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 196. Australia Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 197. Taiwan Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 198. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 199. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2026) & (US$ Million) Table 200. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2027-2032) & (US$ Million) Table 201. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (k units) Table 202. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2027-2032) & (k units) Table 203. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2021-2026) & (US$/unit) Table 204. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Type (2027-2032) & (US$/unit) Table 205. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2026) & (US$ Million) Table 206. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2027-2032) & (US$ Million) Table 207. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026) & (k units) Table 208. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2027-2032) & (k units) Table 209. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2021-2026) & (US$/unit) Table 210. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Application (2027-2032) & (US$/unit) Table 211. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 215. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 216. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 217. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Country (2021-2026) & (US$/unit) Table 218. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Country (2027-2032) & (US$/unit) Table 219. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 220. Argentina Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 221. Chile Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 222. Colombia Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 223. Peru Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 224. Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 225. Israel Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 226. UAE Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 227. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 228. Iran Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 229. Egypt Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Table 230. Key Raw Materials Table 231. Raw Materials Key Suppliers Table 232. Renin-Angiotensin-System (RAS)-Acting Agent Distributors List Table 233. Renin-Angiotensin-System (RAS)-Acting Agent Customers List Table 234. Research Programs/Design for This Report Table 235. Authors List of This Report Table 236. Secondary Sources Table 237. Primary Sources List of Figures Figure 1. Renin-Angiotensin-System (RAS)-Acting Agent Image Figure 2. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Share 2021 VS 2025 VS 2032 Figure 4. Angiotensin Converting Enzyme Inhibitors (ACEi) Image Figure 5. Angiotensin Receptor Blockers (ARBs) Image Figure 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Share 2021 VS 2025 VS 2032 Figure 8. Heart Failure Image Figure 9. Chronic Kidney Disease Image Figure 10. Hypertension Image Figure 11. Other Image Figure 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Figure 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2021-2032) Figure 17. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (2021-2032) & (k units) Figure 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 19. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Renin-Angiotensin-System (RAS)-Acting Agent Sales YoY (2021-2032) & (k units) Figure 21. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales YoY (2021-2032) & (k units) Figure 22. China Renin-Angiotensin-System (RAS)-Acting Agent Sales YoY (2021-2032) & (k units) Figure 23. Asia (Excluding China) Renin-Angiotensin-System (RAS)-Acting Agent Sales YoY (2021-2032) & (k units) Figure 24. South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales YoY (2021-2032) & (k units) Figure 25. Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2032) Figure 31. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2032) Figure 34. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2021-2032) Figure 37. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 38. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2032) Figure 40. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Type (2021-2032) Figure 41. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Type (2021-2032) Figure 42. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Application (2021-2032) Figure 43. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Application (2021-2032) Figure 44. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country (2021-2032) Figure 45. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Country (2021-2032) Figure 46. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Type (2021-2032) Figure 47. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Type (2021-2032) Figure 48. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Application (2021-2032) Figure 49. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Application (2021-2032) Figure 50. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country (2021-2032) Figure 51. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Country (2021-2032) Figure 52. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Type (2021-2032) Figure 53. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Type (2021-2032) Figure 54. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Application (2021-2032) Figure 55. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Application (2021-2032) Figure 56. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Type (2021-2032) Figure 57. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Type (2021-2032) Figure 58. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Application (2021-2032) Figure 59. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Application (2021-2032) Figure 60. Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country (2021-2032) Figure 61. Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Country (2021-2032) Figure 62. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Type (2021-2032) Figure 63. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Type (2021-2032) Figure 64. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Application (2021-2032) Figure 65. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Application (2021-2032) Figure 66. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country (2021-2032) Figure 67. SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Country (2021-2032) Figure 68. Renin-Angiotensin-System (RAS)-Acting Agent Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Renin-Angiotensin-System (RAS)-Acting Agent Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Angiotensin Converting Enzyme Inhibitors (ACEi)
  • Angiotensin Receptor Blockers (ARBs)
Applications
  • Heart Failure
  • Chronic Kidney Disease
  • Hypertension
  • Other
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Daiichi Sankyo Company,Limited
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Boehringer lngelheim GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Renin-Angiotensin-System (RAS)-Acting Agent Market by Type
  3. 1.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Angiotensin Converting Enzyme Inhibitors (ACEi)
  5. 1.2.3 Angiotensin Receptor Blockers (ARBs)
  6. 1.3 Renin-Angiotensin-System (RAS)-Acting Agent Market by Application
  7. 1.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Heart Failure
  9. 1.3.3 Chronic Kidney Disease
  10. 1.3.4 Hypertension
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Renin-Angiotensin-System (RAS)-Acting Agent Market Dynamics
  1. 2.1 Renin-Angiotensin-System (RAS)-Acting Agent Industry Trends
  2. 2.2 Renin-Angiotensin-System (RAS)-Acting Agent Industry Drivers
  3. 2.3 Renin-Angiotensin-System (RAS)-Acting Agent Industry Opportunities and Challenges
  4. 2.4 Renin-Angiotensin-System (RAS)-Acting Agent Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region
  3. 3.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2021-2026)
  5. 3.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2027-2032)
  6. 3.2.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region
  9. 3.4.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2026)
  11. 3.4.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2027-2032)
  12. 3.4.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Manufacturers
  2. 4.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Manufacturers
  6. 4.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Renin-Angiotensin-System (RAS)-Acting Agent Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers, Product Type & Application
  13. 4.7 Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market CR5 and HHI
  16. 4.8.2 2025 Renin-Angiotensin-System (RAS)-Acting Agent Tier 1, Tier 2, and Tier 3
5 Renin-Angiotensin-System (RAS)-Acting Agent Market by Type
  1. 5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type
  2. 5.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
  6. 5.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2032)
  9. 5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Type
6 Renin-Angiotensin-System (RAS)-Acting Agent Market by Application
  1. 6.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application
  2. 6.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
  6. 6.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2032)
  9. 6.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Application
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Company Limited
  2. 7.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 7.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 7.1.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 7.2 Sanofi S.A.
  8. 7.2.1 Sanofi S.A. Company Information
  9. 7.2.2 Sanofi S.A. Business Overview
  10. 7.2.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  12. 7.2.5 Sanofi S.A. Recent Developments
  13. 7.3 Johnson & Johnson
  14. 7.3.1 Johnson & Johnson Company Information
  15. 7.3.2 Johnson & Johnson Business Overview
  16. 7.3.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  18. 7.3.5 Johnson & Johnson Recent Developments
  19. 7.4 Novartis AG
  20. 7.4.1 Novartis AG Company Information
  21. 7.4.2 Novartis AG Business Overview
  22. 7.4.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  24. 7.4.5 Novartis AG Recent Developments
  25. 7.5 Merck & Co., Inc.
  26. 7.5.1 Merck & Co., Inc. Company Information
  27. 7.5.2 Merck & Co., Inc. Business Overview
  28. 7.5.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  30. 7.5.5 Merck & Co., Inc. Recent Developments
  31. 7.6 Pfizer, Inc.
  32. 7.6.1 Pfizer, Inc. Company Information
  33. 7.6.2 Pfizer, Inc. Business Overview
  34. 7.6.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  36. 7.6.5 Pfizer, Inc. Recent Developments
  37. 7.7 Daiichi Sankyo Company,Limited
  38. 7.7.1 Daiichi Sankyo Company,Limited Company Information
  39. 7.7.2 Daiichi Sankyo Company,Limited Business Overview
  40. 7.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  42. 7.7.5 Daiichi Sankyo Company,Limited Recent Developments
  43. 7.8 AstraZeneca plc
  44. 7.8.1 AstraZeneca plc Company Information
  45. 7.8.2 AstraZeneca plc Business Overview
  46. 7.8.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  48. 7.8.5 AstraZeneca plc Recent Developments
  49. 7.9 Bristol-Myers Squibb Company
  50. 7.9.1 Bristol-Myers Squibb Company Company Information
  51. 7.9.2 Bristol-Myers Squibb Company Business Overview
  52. 7.9.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  54. 7.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 7.10 Boehringer lngelheim GmbH
  56. 7.10.1 Boehringer lngelheim GmbH Company Information
  57. 7.10.2 Boehringer lngelheim GmbH Business Overview
  58. 7.10.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  60. 7.10.5 Boehringer lngelheim GmbH Recent Developments
8 North America
  1. 8.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Type
  2. 8.1.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2032)
  3. 8.1.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032)
  4. 8.1.3 North America Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2021-2032)
  5. 8.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Application
  6. 8.2.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2032)
  7. 8.2.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032)
  8. 8.2.3 North America Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2021-2032)
  9. 8.3 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
  10. 8.3.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Renin-Angiotensin-System (RAS)-Acting Agent Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Type
  2. 9.1.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2032)
  3. 9.1.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032)
  4. 9.1.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2021-2032)
  5. 9.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Application
  6. 9.2.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2032)
  7. 9.2.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032)
  8. 9.2.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2021-2032)
  9. 9.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
  10. 9.3.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Type
  2. 10.1.1 China Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2032)
  3. 10.1.2 China Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032)
  4. 10.1.3 China Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2021-2032)
  5. 10.2 China Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Application
  6. 10.2.1 China Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2032)
  7. 10.2.2 China Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032)
  8. 10.2.3 China Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Type
  2. 11.1.1 Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2032)
  3. 11.1.2 Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032)
  4. 11.1.3 Asia Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2021-2032)
  5. 11.2 Asia Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Application
  6. 11.2.1 Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2032)
  7. 11.2.2 Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032)
  8. 11.2.3 Asia Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2021-2032)
  9. 11.3 Asia Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
  10. 11.3.1 Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Renin-Angiotensin-System (RAS)-Acting Agent Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Type
  2. 12.1.1 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2021-2032)
  5. 12.2 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Application
  6. 12.2.1 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2021-2032)
  9. 12.3 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
  10. 12.3.1 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Renin-Angiotensin-System (RAS)-Acting Agent Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Renin-Angiotensin-System (RAS)-Acting Agent Value Chain Analysis
  2. 13.1.1 Renin-Angiotensin-System (RAS)-Acting Agent Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Renin-Angiotensin-System (RAS)-Acting Agent Production Mode & Process
  6. 13.2 Renin-Angiotensin-System (RAS)-Acting Agent Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Renin-Angiotensin-System (RAS)-Acting Agent Distributors
  9. 13.2.3 Renin-Angiotensin-System (RAS)-Acting Agent Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst